References
  1. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Rel Dis 2017;2(3):137e52 [Review Article].
  2. Stochmal, A., Czuwara, J., Trojanowska, M., & Rudnicka, L. (2020). Anti-nuclear Antibodies in Systemic Sclerosis : an Update. January 2019, 40–51.
  3. Patterson, K. A., Lester, S., Tan, J. A., Hakendorf, P., Rischmueller, M., Zochling, J., Sahhar, J., Nash, P., Roddy, J., Hill, C., Nikpour, M., Stevens, W., Proudman, S. M., & Walker, J. G. (2015). Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis ( Scleroderma ) Cohort Using Principal Components Analysis. 67(12), 3234–3244. https://doi.org/10.1002/art.39316
  4. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun. Rev. 2013;12(3):340–54.
  5. Kayser C, Frıtzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol 2015; 6: 1-6.
  6. LeRoy EC, Medsger TA, Jr. Criteria for the classi­fication of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
  7. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M; EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011 Mar;70(3):476-81. doi: 10.1136/ard.2010.136929. Epub 2010 Nov 15. PMID: 21081523.
  8. Domsıc RT. Scleroderma: the role of serum au¬toantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheuma¬tol 2014; 26: 646-52.
  9. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747e55.
  10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
  11. Nihtyanova, S. I., Sari, A., Harvey, J. C., Leslie, A., Derrett-smith, E. C., Fonseca, C., Ong, V. H., & Denton, C. P. (2020). Using Autoantibodies and Cutaneous Subset to Develop Based Disease Classification in Systemic Sclerosis. 72(3), 465–476. https://doi.org/10.1002/art.41153
  12. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011;13(5):R172.
  13. Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, Meyer W, Bogdanos DP, Sakkas LI. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017 Nov;50(7):414-421. doi: 10.1080/08916934.2017.1357699. Epub 2017 Jul 27. PMID: 28749191.
  14. Didier K, Bolko L, Giusti D, et al. Auto-antibodies associated with connec- tive tissue diseases: what meaning for clinicians? Front Immunol 2018 ; 9:541 , .
  15. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003 May;29(2):255-73, vi. doi: 10.1016/s0889-857x(03)00023-1. PMID: 12841294.
  16. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65: 2737–47.
  17. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285
  18. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35:458–465
  19. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022 Aug 30:2200879. doi: 10.1183/13993003.00879-2022. Epub ahead of print. PMID: 36028254.
  20. Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L. Scleroderma renal crisis. J Rheumatol. 2014 Jun;41(6):1040-8. doi: 10.3899/jrheum.131210. Epub 2014 May 15. PMID: 24833760.
  21. Husson F, Josse J, Le S,Mazet J. Multivariate exploratory data analysis and data mining with R: an R package for exploratory data analysis. FactoMineR package version 1.25. 2013. URL: http://factominer.free.fr.
  22. M. Inanc1, M. Birlik2, M. Onat3, Z. Ozbalkan4, F. Yargucu5, T. Kasifoglu6, O.N. Pamuk7, S. Yavuz8, V. Yazisiz9, T. Senturk10, E. Erken11, F. Syswatch Investigators12 Annals of the Rheumatic Diseases, volume 68, supplement 3, year 2009, page 610
  23. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclero- 894 sis. Autoimmun Rev 2013;12:340–354. http://dx.doi.org/10.1016/j.autrev. 895 2012.05.011
  24. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine. 2006 Oct;73(5):490-4. doi: 10.1016/j.jbspin.2006.01.022. Epub 2006 Jun 2. PMID: 16798048.
  25. Choi MY, Fritzler MJ. Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. Curr Opin Rheumatol. 2016 Nov;28(6):586-94. doi: 10.1097/BOR.0000000000000325. PMID: 27387266; PMCID: PMC5029444.
  26. Sibanda EN, Dube Y, Chakawa M, Mduluza T, Mutapi F. Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates. Front Immunol. 2021 Nov 9;12:679531. doi: 10.3389/fimmu.2021.679531. PMID: 34858387; PMCID: PMC8631108.
  27. Yayla ME, İlgen U, Düzgün N. An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis. Turk J Med Sci. 2018 Feb 23;48(1):10-15. doi: 10.3906/sag-1708-67. PMID: 29479936.
  28. Nandiwada SL, Peterson LK,MayesMD, Jaskowski TD,Malmberg E, AssassiS, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol. (2016) 43:1816–24. doi: 10.3899/jrheum.160106
  29. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15:102–9
  30. Tan EM. Anti-nuclear antibodies in Scleroderma. Int J Dermatol 1981;20:569–73
  31. Nakamura RM, Tan EM. Recent advances in laboratory tests and the significance of autoantibodies to nuclear antigens in systemic rheumatic diseases. Clin Lab Med 1986;6:41–53
  32. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford). 2009 Dec;48(12):1570-4. doi: 10.1093/rheumatology/kep290. Epub 2009 Oct 5. PMID: 19808694
  33. Mahler M et al (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014:315179
  34. Hudson M et al (2012) Clinical signifcance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50
  35. Hudson M, Ghossein C, Steen V, Scleroderma Renal Crisis, La Presse Medicale’ (2021), doi: https://doi.org/10.1016/j.lpm.2021.104063
  36. Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M, Fritzler MJ. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity. 2015;48(8):542-51. doi: 10.3109/08916934.2015.1077231. Epub 2015 Aug 31. PMID: 26334795.
  37. Koschik II R. W., N. Fertig, M. R. Lucas, et al. 2012. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin. Exp. Rheumatol. 30(2 Suppl 71): S12–S16.
  38. Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316. PMID: 26246178.
Table 1 . Demographic, clinical, and laboratory characteristics of the SSc patients